On Wednesday, Moderna Inc (MRNA.O) said that their COVID-19 vaccine booster, which targets both the original coronavirus strain and Omicron, exhibited a greater immune response against the variation than the original vaccination.
In one trial, the booster increased virus-neutralizing antibodies by eightfold. The vaccination was generally well-tolerated, with side effects equivalent to a 50 microgram booster dose of mRNA-1273.
“We are submitting our preliminary data and analysis to regulators with the hope that the Omicron-containing bivalent booster will be available in the late summer,” said CEO Stephane Bancel in a statement.
In premarket trading, Moderna shares were up 2%.